Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Business
Archived
•
September 21, 2026
•
9 views
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Source: CNBC Top | https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&id=100003114 - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



